Source: Eur Respir J 2002; 20: 47S-50S



Rating:

Share or cite this content

Citations should be made in the following way:
Kips J.C., Inman M.D., Jayaram L., Bel E.H., Parameswaran K., Pizzichini M.M.M., Pavord I.D., Djukanovic R., Hargreave F.E., Sterk P.J.. The use of induced sputum in clinical trials. Eur Respir J 2002; 20: 47S-50S

Member's Comments

No comment yet.

Related content which might interest you: Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Safety of sputum induction in asthmatics in clinical practice Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomized controlled trial Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Sample sizes for clinical trials using sputum eosinophils as a primary outcome Source: Eur Respir J 2013; 42: 1003-1011 Year: 2013 Clinical application of induced sputum Source: Annual Congress 2008 - Biomarkers in COPD - application in clinical and epidemiological studies Year: 2008 Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 A rapid method to increase the clinical use of sputum inflammatory cells Source: International Congress 2017 – Techniques in biomarker selection Year: 2017 Relative sensitivity of markers of activated eosinophils in clinical trials for asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 LAM clinical trials and the state-of-the-art Source: International Congress 2014 – Advances in care for patients with lymphangioleiomyomatosis (LAM) Year: 2014 Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial> Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 The success of obtaining the induced sputum of patients with COPD Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses Year: 2019 COPD treatment from pathophysiology to clinical trials Source: ERS Live 2007 Year: 2007 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Interleukine-13 in induced sputum in clinical remission asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 175s Year: 2003 A cholesterol-rich diet accelerates the negativization of sputum culture in pulmonary tuberculosis: a controlled clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002 No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018